Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis. (ASCLEPIOS II)

NCT02792231 PHASE3 COMPLETED Results posted

To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis

Details

Lead sponsor	Novartis Pharmaceuticals
Phase	PHASE3
Status	COMPLETED
Enrolment	955
Start date	Fri Aug 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Oct 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Relapsing Multiple Scelrosis

Interventions

• Ofatumumab subcutaneous injection
• Teriflunomide-matching placebo capsules
• Teriflunomide capsule
• Matching placebo of ofatumumab subcutaneous injections

Countries

Italy, Finland, Taiwan, Poland, Croatia, Russia, Belgium, Mexico, Lithuania, Bulgaria, Czechia, Portugal, United States, Latvia, France, South Africa, Slovakia, Austria, Hungary, Norway, Argentina, Canada, Spain, Peru, United Kingdom, Germany, Switzerland, Australia, Turkey (Türkiye), India